Mouse IgG - Isotype Control (ab37355)
製品の概要
-
製品名
Mouse IgG - Isotype Control
Mouse アイソタイプ・コントロール 製品一覧 -
特異性
This antibody has been selected as an isotype control as it has no known specificity.
-
アプリケーション
適用あり: ELISA, Flow Cyt, IHCmore details -
特記事項
The Life Science industry has been in the grips of a reproducibility crisis for a number of years. Abcam is leading the way in addressing this with our range of recombinant monoclonal antibodies and knockout edited cell lines for gold-standard validation. Please check that this product meets your needs before purchasing.
If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, along with publications, customer reviews and Q&As
製品の特性
-
製品の状態
Liquid -
保存方法
Shipped at 4°C. Upon delivery aliquot. Store at -20°C long term. Avoid freeze / thaw cycle. -
バッファー
pH: 8.20
Constituent: 100% Borate buffered saline -
Concentration information loading...
-
精製度
Affinity purified -
特記事項(精製)
Purified from normal mouse serum. -
ポリ/モノ
ポリクローナル -
アイソタイプ
IgG -
研究分野
-
別名
- Mouse Isotype Control
関連製品
-
Compatible Secondaries
アプリケーション
The Abpromise guarantee
Abpromise保証は、 次のテスト済みアプリケーションにおけるab37355の使用に適用されます
アプリケーションノートには、推奨の開始希釈率がありますが、適切な希釈率につきましてはご検討ください。
アプリケーション | Abreviews | 特記事項 |
---|---|---|
ELISA |
Use at an assay dependent concentration.
|
|
Flow Cyt |
Use at an assay dependent concentration.
ab37355 - Mouse polyclonal IgG, is suitable for use as an isotype control with this antibody.
|
|
IHC |
Use at an assay dependent concentration.
|
特記事項 |
---|
ELISA
Use at an assay dependent concentration. |
Flow Cyt
Use at an assay dependent concentration. ab37355 - Mouse polyclonal IgG, is suitable for use as an isotype control with this antibody.
|
IHC
Use at an assay dependent concentration. |
画像
プロトコール
データシートおよび資料
-
SDS download
-
Datasheet download
参考文献 (65)
ab37355 は 65 報の論文で使用されています。
- Nataraj NB et al. Nucleoporin-93 reveals a common feature of aggressive breast cancers: robust nucleocytoplasmic transport of transcription factors. Cell Rep 38:110418 (2022). PubMed: 35196484
- Wang L et al. High farnesoid X receptor expression predicts favorable clinical outcomes in PD‑L1low/negative non‑small cell lung cancer patients receiving anti‑PD‑1‑based chemo‑immunotherapy. Int J Oncol 60:N/A (2022). PubMed: 35211760
- Melendez E et al. Natural killer cells act as an extrinsic barrier for in vivo reprogramming. Development 149:N/A (2022). PubMed: 35420133
- Chen L et al. Circ_0004087 interaction with SND1 promotes docetaxel resistance in prostate cancer by boosting the mitosis error correction mechanism. J Exp Clin Cancer Res 41:194 (2022). PubMed: 35659274
- Zhu C et al. An intranasal ASO therapeutic targeting SARS-CoV-2. Nat Commun 13:4503 (2022). PubMed: 35922434